Biogelx Ltd.
Hydrogel scaffolds to support in vitro cell culture
This article was originally published in Start Up
Executive Summary
Cultured cells are important for learning about the basic biology of health and disease, for in vitro testing of new drugs, and potentially for the growing field of regenerative medicine, but flat sheets of cells grown in Petri dishes do not reflect the complexity of tissues in the human body. Biogelx Ltd. aims to meet this need by creating hydrogel scaffolds that mimic the cell growth environment in tissues and organs, and are specifically tailored to match each cell type.
You may also be interested in...
Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
Redx Pharma PLC
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.